CASI PHARMACEUTICALS
CASI Pharmaceuticals, Inc. ("CASI", "we" or "us") is a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products in China, the United States, and throughout the world. CASI is focused on acquiring, developing and commercializing products that augment its hematology oncology therapeutic focus as well as other areas of unmet medical need. CASI is executing its plan to become a biopharmaceutical leader by launching medicines in the greater China market leveraging CASI's China-based regulatory and commercial competencies and its global drug development expertise.
CASI PHARMACEUTICALS
Social Links:
Industry:
Biotechnology Medical Pharmaceutical
Founded:
1991-01-01
Address:
Rockville, Maryland, United States
Country:
United States
Website Url:
http://www.casipharmaceuticals.com
Total Employee:
101+
Status:
Active
Contact:
(240) 864-2643
Email Addresses:
[email protected]
Total Funding:
147.38 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Google Analytics Apple Mobile Web Clips Icon Google Universal Analytics Nginx Euro
Similar Organizations
Advanced Cell Diagnostics
Advanced Cell Diagnostics is a molecular pathology company developing cell- and tissue-based diagnostic tests for personalized medicine.
Salix Pharmaceuticals
Salix Pharmaceuticals is a specialty pharmaceutical company focused on the prevention and treatment of gastrointestinal disorders.
Current Employees Featured
Founder
Stock Details
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 2006-01-10 | Miikana Therapeutics | Miikana Therapeutics acquired by CASI Pharmaceuticals | 9.96 M USD |
Investors List
Robert W. Duggan
Robert W. Duggan investment in Post-IPO Equity - CASI Pharmaceuticals
ETP Fund
ETP Fund investment in Post-IPO Equity - CASI Pharmaceuticals
IDG Capital
IDG Capital investment in Post-IPO Equity - CASI Pharmaceuticals
IDG Capital
IDG Capital investment in Post-IPO Equity - CASI Pharmaceuticals
Emerging Technology Partners
Emerging Technology Partners investment in Post-IPO Equity - CASI Pharmaceuticals
Accel
Accel investment in Post-IPO Equity - CASI Pharmaceuticals
Oxford Finance LLC
Oxford Finance LLC investment in Post-IPO Debt - CASI Pharmaceuticals
GE Healthcare
GE Healthcare investment in Post-IPO Debt - CASI Pharmaceuticals
Merrill Lynch
Merrill Lynch investment in Post-IPO Debt - CASI Pharmaceuticals
Investments List
| Date | Company | Article | Money raised |
|---|---|---|---|
| 2022-07-08 | Precision Autoimmune Therapeutics | CASI Pharmaceuticals investment in Venture Round - Precision Autoimmune Therapeutics | 140 M CNY |
| 2019-07-09 | Juventas | CASI Pharmaceuticals investment in Series A - Juventas | 100 M CNY |
Official Site Inspections
http://www.casipharmaceuticals.com Semrush global rank: 1.53 M Semrush visits lastest month: 17.33 K
- Host name: staticip2.multiscreensite.com
- IP address: 100.24.208.97
- Location: Ashburn United States
- Latitude: 39.0481
- Longitude: -77.4728
- Metro Code: 511
- Timezone: America/New_York
- Postal: 20149
More informations about "CASI Pharmaceuticals"
CASI Pharmaceuticals
CID-103 is an investigational monoclonal antibody. Its targets include B memory, plasmablasts, and B plasma cells. The anti-CD38 approach aims to address limitations seen with CD19 and …See details»
CASI Pharmaceuticals - Crunchbase Company Profile
Contact Email [email protected] Phone Number (240) 864-2643 CASI Pharmaceuticals, Inc. ("CASI", "we" or "us") is a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and …See details»
CASI Pharmaceuticals - Wikipedia
CASI Pharmaceuticals, previously known as EntreMed is a US based pharmaceutical company developing medicinal treatments for cancer. The company is primarily known for its producing the angiogenesis inhibitor Endostatin. In 2014 the company was renamed to CASI Pharmaceuticals to focus on products for the treatments of myeloma, leukemia, lymphoma. Wei-Wu He is the present chairman and CEO of the company. See details»
Investor Overview - CASI Pharmaceuticals
CASI Pharmaceuticals, Inc. is followed by the analyst(s) listed below. This list is provided for information purposes only. Please note that any opinions, estimates or forecasts regarding …See details»
CASI Pharmaceuticals, Inc. | LinkedIn
CASI Pharmaceuticals, Inc. | 1,095 followers on LinkedIn. Bringing life-changing therapeutics to China and the world. | CASI is a U.S. NASDAQ-listed biopharmaceutical company focused on developing ...See details»
CASI Pharmaceuticals, Inc. (CASI) Company Profile & Facts - Yahoo …
See the company profile for CASI Pharmaceuticals, Inc. (CASI) including business summary, industry/sector information, number of employees, business summary, corporate governance, …See details»
CASI Pharmaceuticals, Inc. (CASI) Company Profile & Overview
Jun 11, 1996 1701-1702, China Central Office Tower 1, No. 81 Jianguo Road Beijing, 100025 ChinaSee details»
CASI Pharmaceuticals, Inc. (CASI) - Stock Analysis
5 days ago Website https://www.casipharmaceuticals.com. Full Company Profile. Financial Performance. In 2023, CASI Pharmaceuticals's revenue was $33.88 million, a decrease of -21.41% compared to the previous year's $43.11 …See details»
CASI Pharmaceuticals - Overview, News & Similar companies
Mar 28, 2024 View CASI Pharmaceuticals (www.casipharmaceuticals.com) location in China , revenue, industry and description. Find related and similar companies as well as employees …See details»
CASI Pharmaceuticals - Craft
Aug 15, 2024 CASI Pharmaceuticals has 5 employees across 2 locations and $43.11 m in annual revenue in FY 2022. See insights on CASI Pharmaceuticals including office locations, …See details»
CASI Pharmaceuticals Files Annual Report on Form 20-F for Fiscal …
Apr 26, 2023 CASI is a NASDAQ-listed biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products.See details»
CASI Pharmaceuticals, Inc. (CASI) - Yahoo Finance
Find the latest CASI Pharmaceuticals, Inc. (CASI) stock quote, history, news and other vital information to help you with your stock trading and investing.See details»
CASI Pharmaceuticals announces appointment of Daniel Lang, MD …
Jul 8, 2024 CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a Cayman incorporated biopharmaceutical company focused on developing and commercializing innovative …See details»
CASI.A - | Stock Price & Latest News | Reuters
6 days ago Get CASI Pharmaceuticals Inc (CASI.A) real-time stock quotes, news, price and financial information from Reuters to inform your trading and investmentsSee details»
CASI PHARMACEUTICALS ANNOUNCES FOURTH QUARTER AND …
CASI Pharmaceuticals logo (PRNewsFoto/CASI Pharmaceuticals, Inc.) CASI reported fourth quarter 2023 revenue of $6.9 million for EVOMELA ®, 33% lower than the same period in …See details»
CASI Pharmaceuticals Announces Third Quarter 2023 Financial …
BEIJING, China (November 14, 2023) CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a biopharmaceutical company focused on developing and commercializing innovative …See details»
CASI Stock Price Quote | Morningstar
6 days ago See the latest CASI Pharmaceuticals Inc stock price (CASI:XNAS), related news, valuation, dividends and more to help you make your investing decisions.See details»
CASI PHARMACEUTICALS ANNOUNCES FIRST QUARTER 2024 …
May 14, 2024 CASI Pharmaceuticals logo (PRNewsFoto/CASI Pharmaceuticals, Inc.) In the first quarter of 2024, CASI's total revenue was $3.4 million.Total revenue decreased by 59% …See details»
CASI Pharmaceuticals, Inc. (CASI) - Yahoo Finance
Get the latest CASI Pharmaceuticals, Inc. (CASI) stock news and headlines to help you in your trading and investing decisions.See details»